Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway

Cisplatin has been the most accepted drug for the treatment of ovarian cancer for almost 40 years. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, many patients will develop cisplatin-resistance disease, which is extremely rapid and fata...

Descripción completa

Detalles Bibliográficos
Autores principales: Echevarría-Vargas, Ileabett M., Valiyeva, Fatma, Vivas-Mejía, Pablo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035252/
https://www.ncbi.nlm.nih.gov/pubmed/24865582
http://dx.doi.org/10.1371/journal.pone.0097094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035252/
https://www.ncbi.nlm.nih.gov/pubmed/24865582
http://dx.doi.org/10.1371/journal.pone.0097094

Ejemplares similares